S M Short1, W Rubas, B D Paasch, R J Mrsny. 1. Pharmaceutical Research and Development, Genentech Inc., South San Francisco, California 94080, USA.
Abstract
PURPOSE: Several studies have suggested epidermal uptake of cytokines, such as interferons, can be facilitated using topical liposomal formulations. We have evaluated the in vitro transport of biologically active recombinant human interferon-gamma (rhIFN-gamma) into and through split-thickness human skin to assess this possibility. METHODS: Skin samples were exposed to rhIFN-gamma under various conditions involving hydrated and dry surface conditions in the presence and absence of liposomes. A new low-level ELISA and an anti-viral bioassay were used to quantitate transported rhIFN-gamma. Immunohistochemical staining for ICAM-1 expression by keratinocytes was used to visualize the extent and distribution of rhIFN-gamma transport. RESULTS: Apparent steady-state transport of rhIFN-gamma occurred within the first 5 hours of exposure with approximately 10% of transported rhIFN-gamma demonstrating bioactivity. While the permeability of rhIFN-gamma across human skin under drying conditions was enhanced by the presence of liposomes, no augmentation of permeability was observed when the skin was kept hydrated. Liposomal formulations of rhIFN-gamma had greater transport rates than aqueous formulations when the applied formulations were allowed to dry after dosing. CONCLUSIONS: Our results demonstrate the transport of biologically active rhIFN-gamma across human skin in vitro and suggest a role for stratum corneum hydration as one possibility for the augmented cytokine transport.
PURPOSE: Several studies have suggested epidermal uptake of cytokines, such as interferons, can be facilitated using topical liposomal formulations. We have evaluated the in vitro transport of biologically active recombinant humaninterferon-gamma (rhIFN-gamma) into and through split-thickness human skin to assess this possibility. METHODS: Skin samples were exposed to rhIFN-gamma under various conditions involving hydrated and dry surface conditions in the presence and absence of liposomes. A new low-level ELISA and an anti-viral bioassay were used to quantitate transported rhIFN-gamma. Immunohistochemical staining for ICAM-1 expression by keratinocytes was used to visualize the extent and distribution of rhIFN-gamma transport. RESULTS: Apparent steady-state transport of rhIFN-gamma occurred within the first 5 hours of exposure with approximately 10% of transported rhIFN-gamma demonstrating bioactivity. While the permeability of rhIFN-gamma across human skin under drying conditions was enhanced by the presence of liposomes, no augmentation of permeability was observed when the skin was kept hydrated. Liposomal formulations of rhIFN-gamma had greater transport rates than aqueous formulations when the applied formulations were allowed to dry after dosing. CONCLUSIONS: Our results demonstrate the transport of biologically active rhIFN-gamma across human skin in vitro and suggest a role for stratum corneum hydration as one possibility for the augmented cytokine transport.